Please assess the completion status of the following clinical trial:

Trial Title: Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 to 16 years old. Body weight between 20 to 60 kg~* Meet ADHD criteria in tne Diagnostic and Statistic Manual of Mental Disorders, fourth edition (DSM-IV) through questionaire and interview~* Intelligence quotient (IQ) \>= 70~* Currently unmedicated or effectively medicated with immediately released methylphenidate (The maximum dosage no more than 60mg/d)~* The patient and the parent express their will to comply with the follow up including the clinical interview and all the test~* The parent or the guardian sign the written consent~* Can swallow the capsule~Exclusion Criteria:~* Have administered immediate release methylphenidate, OROS MPH or atomoxetine, but ADHD symptoms not improved.~* Bipolar I or II disorder, psychosis, or pervasive developmental disorder.~* Meet the DSM-IV anxiety disorder.~* Any seizure disorder (except for febrile convulsion) or electroencephalogram (EEG) abnormal associated with epilepsy, or currently taking anti-convulsion drugs.~* Depression disorder, tend to commit suicide, or comorbid depression symptoms which need immediate treatment.~* Tics disorder, or Tourette's syndrom（DSM-IV 307.23）, or family history of tics disorder.~* Narrow-angle glaucoma~* cardiovascular diseases, or any diseases may be deteriorated when the pulse or the blood pressure increased, including hypertension or those taking anti-hypertension drugs.~* Diseases significantly enhance the sympathetic nervous system activity, or taking sympathomimetic drug every day.~* Allergic to methylphenidate or atomoxetine, or serious allergic reaction to more than one drugs or adverse event to multiple drugs before.~* Serious gastrointestinal stenosis~* History of alcohol, drug or other substance abuse~* Those using unprescribed potential abuse drugs in screening.~* In the process of the trial, the patient need to take other psychotropic drug other than the experimental drugs, including health food with central nervous system (CNS) activity (e.g. melatonin).~* Might begin any structure psychological therapy addressed for ADHD in the process of the trial~* Have used other psychotropic drugs in the past 30 days, including monoamine oxidase inhibitor.~* Are participating other clinical trial.~* Have difficulty in following up in 8 weeks.~* Relatives of the investigator.~* Employee of Xi-an Jensen or Eli lilly company.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- OROS MPH (Type: EXPERIMENTAL): the group treated by OROS MPH
- atomoxetine (Type: ACTIVE_COMPARATOR): the group treated by atomoxetine
- control (Type: NO_INTERVENTION): the normal control with no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).